Barbara Staehelin, CEO
(1963, Swiss, American, CEO). M. Sc. Biochemistry ETH, MBA INSEAD, Health Economist. F. Hoffmann-La Roche, Executive Committee member Diagnostics division, head of Clinical and Market development, head of Licensing and Alliances. Prior to Roche, five years entrepreneur (international health care provider company) and winner of the Veuve Clicquot business woman of the year award. Six years pharmaceutical and healthcare consulting with McKinsey & Co.

Henri Zinsli, Chairman
(1941, Swiss, Chairman, CFO). PhD Economics 
St. Gallen. Ciba-Geigy, Global Business Unit Head pioneering modern therapeutic area development management, deputy head Global Pharma Product Management and executive member Global Marketing Management, product manager CVD therapeutics. Head Corporate Business Development, Manager Corporate Venture Capital. Co-founder, board member or chairman of several biotech companies: Discovery Partners International AG, Speedel

Herman Kempen, CSO
(1947, Dutch, CSO). PhD Biochemistry University of Nijmegen. Head of research and drug discovery teams in the area of lipids and atherosclerosis for 18 years, published 90 papers and several patents. Gaubius Institute TNO, Leiden, member of the institute’s Management Team and leader of the Lipid and Atherosclerosis Group. Recruited to head up the Biology Department Metabolic Diseases Research at F. Hoffmann-La Roche in Basel. Broad business development and licensing experience and extensive network in the cardiovascular field (Roche, Speedel, LODH, ultreia).
For an example of Herman's publications, click here. For the list of publications available in PubMed, please enter the search term "Kempen HJ" on the PubMed site here.